CKD-Induced Anemia Revisited: Interplay of inflammation, Iron, and Novel Therapies

CKD anaemia, commonly referred to as anaemia of chronic renal disease, is a subtype of hypoproliferative anaemia and normocytic normochromic anaemia. This condition is prevalent among people with renal illness and is linked to poor outcomes and a higher risk of death in CKD patients. While there are many similarities between it and the chronic inflammatory elements of CKD anaemia, a significant difference is that CKD anaemia is characterised by a severe erythropoietin shortage. Therefore, the goal of treatment is to increase the generation of red blood cells, decrease functional iron shortage, and improve renal function wherever possible. A full blood count with differential, peripheral smear, and tests to rule out other causes of anaemia, such as B12, folate, haptoglobin, thyroid studies, and iron indices (iron, ferritin, total iron-binding capacity, saturation of transferrin and folate), are necessary for the diagnosis. Iron supplements and erythropoiesis-stimulating agents (ESAs) are presently the mainstays of treatment for anaemia associated with chronic renal illness. Since the first ESA and intravenous iron formulations were used, guidelines have changed considerably, and numerous novel therapeutic approaches are now on the market or being investigated in advanced-phase clinical trials. The assessment and treatment of anaemia in chronic renal illness are reviewed in this activity. In order to provide the best possible care for those impacted by this illness, this activity also emphasises the need of the interprofessional healthcare team.